AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Share price
+$4.94 (+42.77%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aurinia Pharmaceuticals Inc. grew revenue 19.8% to $311.51M over the twelve months to Jun 30, 2026. Operating income rose 189.8% to $150.75M, moving the operating margin from 20.0% to 48.4%.
Revenue
$311.51M
+19.8% vs. a year earlier
Operating income
$150.75M
+189.8% vs. a year earlier
EPS, diluted
$2.29
+432.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.20B
- P/E ratio
- 7.2
- Price to sales
- 7.07
- Price to book
- 3.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $311.51M
- Net income
- $314.11M
- EPS, diluted
- $2.29
- Book value per share
- $4.60
- Diluted shares
- 134M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$311.51M+19.8% YoY
Gross profit
$281.47M+20.9% YoY
Operating income
$150.75M+189.8% YoY
Net income
$314.11M+418.0% YoY
EPS, diluted
$2.29+432.6% YoY
Free cash flow
–
Reported periodTrailing twelve months